A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
Condition: HOCM, Hypertrophic Obstructive Cardiomyopathy Interventions: Drug: Mavacamten; Drug: Placebo Sponsor: MyoKardia, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cardiology | Cardiomyopathy | Heart | Hypertrophic Obstructive Cardiomyopathy | Research | Study